Drugs for Neglected Diseases Initiative (DNDi) and the Japanese pharmaceutical company Eisai found that fosravuconazole works as a treatment for mycetoma, a serious condition.[1][4][5] The Phase II clinical trial found that oral fosravuconazole was safe, patient-friendly, and effective in treating eumycetoma.[6][7] Eumycetoma mainly affects young adults in poorer, rural areas; the standard treatment is itraconazole, which is much more expensive at about US$2,000 for a year than fosravuconazole and unaffordable, and not available in all endemic countries.[7]
References
^ abcYamaguchi H (2016). "Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis". Medical Mycology Journal. 57 (4): E93 –E110. doi:10.3314/mmj.16-00006. PMID27904057.
^"Fosravuconazole". Drugs for Neglected Diseases Initiative. 23 November 2023 [Project started in 2015; updated in 2023 with results of the Phase II clinical trial].